AVIVA SYSTEMS BIOLOGY

×

Error message

  • Warning: socket_connect(): unable to connect [111]: Connection refused in orgtags() (line 159 of /var/www/7/sites/all/modules/jotup/exsumm/lexsumm/orgtags.inc).
  • Warning: socket_write(): unable to write to socket [32]: Broken pipe in orgtags() (line 160 of /var/www/7/sites/all/modules/jotup/exsumm/lexsumm/orgtags.inc).
  • Warning: socket_read(): unable to read from socket [107]: Transport endpoint is not connected in orgtags() (line 161 of /var/www/7/sites/all/modules/jotup/exsumm/lexsumm/orgtags.inc).

Associated tags: Research, Proteomics, Aviva, Antibody, Immunoprecipitation, Vaccine, IHC, SAN, Protein, A-DNA, ELISA, Fine chemical, Health

Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing

Retrieved on: 
Monday, January 9, 2023

This partnership seeks to co-develop protein enrichment kits to enable deep interrogation of proteins of interest and their variants (proteoforms) through protein sequencing.

Key Points: 
  • This partnership seeks to co-develop protein enrichment kits to enable deep interrogation of proteins of interest and their variants (proteoforms) through protein sequencing.
  • The co-developed products will include immunoprecipitation kits that fit into existing research workflows to conveniently enrich target proteins prior to amino acid mutation or post-translational modification (PTM) analysis with Quantum-Si’s PlatinumTM protein sequencing platform.
  • "This partnership brings together unique capabilities from Quantium-Si and Aviva Systems Biology that will accelerate new discoveries in protein research," said Kevin Harvey, President of Aviva.
  • "Speeding up new discoveries is a shared goal at Quantum-Si and Aviva Systems Biology, and we are excited to partner with Quantum-Si to drive proteomics research forward."

Aviva Systems Biology Announces the Launch of High Throughput Antibody Characterization Services

Retrieved on: 
Monday, April 11, 2022

SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology , a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its new service offering for high throughput Antibody Characterization Services .

Key Points: 
  • SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology , a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its new service offering for high throughput Antibody Characterization Services .
  • Aviva Systems Biology's Antibody Characterization Services provides drug discovery researchers in small to mid-size biotechs with an affordable and easily accessible solution for rapid screening of therapeutic antibodies, kinetic analysis, and epitope mapping and binning.
  • By leveraging the advanced Carterra LSA platform, Aviva can provide high throughput SPR analysis for biotherapeutic antibody development at a scale other screening providers can't match.
  • We are excited to offer this unique solution to biotherapeutic antibody researchers," said Kevin Harvey, President of Aviva Systems Biology.

Aviva Systems Biology Launches AvivaBlot ECL Reagents for Western Blot

Retrieved on: 
Monday, April 11, 2022

SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology , a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its AvivaBlot product line of ECL reagents for western blot application.

Key Points: 
  • SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology , a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its AvivaBlot product line of ECL reagents for western blot application.
  • To ensure researchers achieve the best from their western blots, the AvivaBlot ECL reagents are easy-to-use, high quality, and affordable for a variety of western blot detection needs.
  • "For nearly 20 years Aviva Systems Biology has supported customers with thousands of antibodies validated in Western Blot, the primary workhorse application for protein analysis in most research settings.
  • We are excited to now provide best-in-class ECL detection reagents that will support Aviva customers complete Western Blot workflow needs," said Kevin Harvey, Ph.D., President.

Aviva Systems Biology Announces the Launch of Protein on Demand™ Semi-Custom Recombinant Protein Portfolio

Retrieved on: 
Wednesday, September 8, 2021

SAN DIEGO, Sept. 8, 2021 /PRNewswire/ -- Aviva Systems Biology, a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its new Protein on Demand semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies.

Key Points: 
  • SAN DIEGO, Sept. 8, 2021 /PRNewswire/ -- Aviva Systems Biology, a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its new Protein on Demand semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies.
  • High quality recombinant proteins are a vital tool to successful life science research.
  • Existing off-the-shelf options are limited, and custom protein expression providers frequently require large minimum production quantities.
  • Aviva Systems Biology, founded in 2002, is a global market leader in proteomics research offering a broad portfolio of polyclonal and monoclonal antibodies, immunoassay kits, recombinant proteins, and custom protein expression and manufacturing services for academic and biopharma researchers.